L2 Diagnostics is a translational research company focused on addressing significant unmet medical needs through innovative research in vaccines, small-molecule therapeutics, and diagnostics. Their vaccine research targets diseases transmitted by insect and tick vectors, such as malaria and Lyme disease, with a unique approach that aims to develop a single vaccine capable of providing protection against multiple diseases by focusing on the molecules produced by the vectors necessary for infection. This research is conducted in collaboration with Yale University, highlighting L2's commitment to leveraging academic partnerships to enhance their scientific endeavors.

In the realm of small-molecule therapeutics, L2 is actively developing treatments for infectious diseases, particularly targeting gram-negative bacteria like Pseudomonas aeruginosa, as well as exploring applications in oncology and immunology. Their research employs a variety of technologies, including structure-based drug design, natural product leads, and high-throughput screening, supported by a network of specialized contract research organizations. Additionally, L2 is advancing diagnostic technologies to create more sensitive assays for diseases such as diabetes and emerging tick-borne infections, as well as developing serology assays in response to the COVID-19 pandemic. Their CLIA-certified diagnostic facility plays a crucial role in this effort, enabling the development of novel assays to meet evolving healthcare challenges.

United States

L2 is a biotechnology company based in New Haven, Connecticut, USA with focus on new small molecule therapeutics, vaccines, and diagnostics

L2 Diagnostics

Company Details